Articles tagged with: BMS-663068
News »
Rate Of New HIV Infections In The U.S. Is Stable – A report issued by the U.S. Centers for Disease Control and Prevention (CDC) last week indicates that the annual rate of new HIV infections has stabilized at about 50,000 new infections per year in the U.S. However, the CDC also found that the rate of new infections rose 48 percent between 2006 and 2009 in young African-American men who have sex with men. Rates for all other race and risk groups remained stable. The CDC noted that most new infections (61 percent) are still among men who have sex with men, although 11 percent of new infections in 2009 were in African-American women, who are now 15 times more likely to contract HIV than Caucasian women. For more information, please see the CDC press release or the report in PLoS One.
Federal Government Reverses Limits On Emergency Funding To State ADAPs – The federal Health Resources and Services Administration (HRSA) has reversed a previous decision to limit emergency funding to AIDS Drug Assistance Programs (ADAPs) to $3 million per state. Instead, states will be allowed to receive at least as much emergency assistance as they received last year. In July, Congress authorized $50 million in emergency funding for ADAPs, which provide free antiretrovirals to low-income people with HIV. Several state ADAPs have faced budget crises, and 13 states currently have waiting lists. Activists protested HRSA’s initial decision to limit the emergency funds to a maximum of $3 million per state, which is less than some states, such as Florida, received last year in emergency funds. For more information, please see the article in The Florida Independent.
Bristol-Myers Squibb Recruits Participants For Phase 2 Clinical Trial Of New Antiretroviral – Bristol-Myers Squibb (BMS) is currently recruiting participants for a Phase 2 clinical trial of its investigational antiretroviral BMS-663068. BMS-663068 is a new type of antiretroviral that prevents HIV from entering and infecting cells. The trial will test the new drug at four different dosages, including both once-daily and twice-daily dosages, in combination with Isentress (raltegravir) and Viread (tenofovir). Eligible participants must have been treated for HIV previously but cannot have taken Isentress. Participants must also have viral loads (amount of HIV in the blood) of 1,000 copies per milliliter or higher. BMS expects to recruit approximately 250 participants. For more information, please see the U.S. Clinical Trials Registry.
Headline, News »
This article is the first in a two-part series discussing Dr. Patrick Yeni’s presentation at the 18th Conference on Retroviruses and Opportunistic Infections, entitled “15 Years of HAART: What Does the Future Hold?” The first article discusses new antiretrovirals and treatments for HIV. The second article discusses ongoing research efforts to find a cure for HIV.
Highly active antiretroviral therapy has improved over the past 15 years and is now more effective, less toxic, and easier to take than earlier treatment regimens. However, there is still room for improvement,…
Espanol »
Este artículo es el primero de una serie de dos en los que se debate sobre la presentación del Dr. Patrick Yeni en la “18ª Conferencia Sobre Retrovirus e Infecciones Oportunistas”, titulada “15 años de la HAART: ¿qué nos depara el futuro?” Este primer artículo analiza los nuevos antirretrovirales y tratamientos para VIH. El segundo artículo habla de los esfuerzos de investigación en curso destinados a encontrar una cura para el VIH.
La terapia antirretroviral altamente activa (HAART, por sus siglas en inglés) ha mejorado en los últimos 15 años…